Intertek Strengthens Solar Assurance Leadership with Acquisition of Mitsui Chemicals Lab in India

Intertek expands in India's solar boom, acquiring a PV testing lab with key accreditations to speed up market access. A strategic bolt-on for growth.

16 April 2026by Joshua Thompson5 min read21 views

This article covers information on Intertek Group PLC.

LON:ITRK

Intertek snaps up Mitsui Chemicals’ solar PV lab assets in India – here’s why it matters

Intertek Group PLC has announced the acquisition of the assets of a state-of-the-art solar photovoltaic (PV) testing laboratory in Ahmedabad, Gujarat, from Mitsui Chemicals India Pvt. Ltd. This is a targeted move into one of the world’s fastest-growing solar markets, aimed squarely at boosting Intertek’s position in renewable energy assurance.

India’s solar push is huge. The Government of India is targeting 500 GW of non-fossil fuel power capacity by 2030, including 280 GW of solar. That tide of investment needs trusted product testing, certification and inspection to get hardware into the market quickly and safely. That is exactly where Intertek plays.

India’s PV boom is tailor-made for Intertek’s assurance model

Solar PV is the fastest-growing renewable technology globally, and India sits at the heart of that transition. When markets scale this fast, manufacturers and developers need independent, accredited labs to validate that modules, components and installations meet national and international standards.

Intertek is leaning into that demand with a local, accredited platform. The company calls out rising demand for Risk-based Quality Assurance – in plain English, focusing testing and inspection where the biggest technical and commercial risks lie, to save time and money while improving reliability.

What exactly did Intertek buy – and what can it do?

The deal is an asset purchase of a solar PV testing laboratory in Ahmedabad. The lab offers comprehensive testing and certification services for PV installations, materials and components, with key accreditations that enable market access in India and beyond.

ISO 17025 accredited testing – this is the international standard for competent testing laboratories.
BIS accreditation – Bureau of Indian Standards, required for many products sold in India.
IECEE CB Scheme – a global system for mutual recognition of test results, which streamlines cross-border approvals.

Intertek says the lab will support both Indian PV manufacturers and international companies entering the Indian market, helping to harmonise testing and speed up approvals. The location in Gujarat also expands Intertek’s footprint in the Western India corridor, a major industrial hub.

Share𝕏 in

Investing
Polar Capital Technology Trust Reports 102% NAV Growth in Stellar Fiscal Year
Polar Capital Technology Trust sees 102% NAV growth in FY2026, beating its benchmark by 47 points thanks to AI and semiconductor exposure.
JoshuaJuly 10, 2026
Investing

Tagged

Last updated

5 July 2026

Star Rating

No ratings yet

Strategic fit: plugging into ATIC and Intertek CEA

This acquisition is explicitly described as complementary to Intertek’s Risk-based Quality Assurance for solar and part of its broader ATIC offering – Assurance, Testing, Inspection and Certification. It also builds on the capabilities of Intertek CEA, which already provides end-to-end solutions for the solar industry, including aerial drone inspections and solar plant inspections.

In other words, Intertek isn’t just buying a lab. It is adding an on-the-ground node that can feed into a wider service stack – from component testing to field inspections – and help customers access markets faster with fewer retests and delays.

Key facts at a glance

Transaction	Acquisition of solar PV testing laboratory assets
Seller	Mitsui Chemicals India Pvt. Ltd.
Location	Ahmedabad, Gujarat, India
Scope	Testing and certification for solar PV installations, materials and components
Accreditations	ISO 17025, BIS, IECEE CB Scheme
Strategic angle	Reinforces Risk-based Quality Assurance and expands Western India footprint
Financial terms	Not disclosed

Why this looks positive for shareholders

Strength in a growth market: India’s 2030 targets – 500 GW non-fossil, including 280 GW of solar – set up a multi-year runway for PV testing and certification demand.
Local accreditation advantage: BIS and IECEE CB credentials matter. Having them in-country reduces friction for manufacturers and accelerates market access.
Cross-sell potential: The lab can feed work into Intertek’s broader ATIC and Intertek CEA services, from design stages to field inspections, lifting wallet share per customer.
Barrier to entry: Accredited, ISO 17025 labs with recognised schemes take time and expertise to build. Acquiring a ready-made, state-of-the-art facility is an efficient route to scale.
CEO alignment: Management is clearly leaning into solar. The CEO highlights India as a leading solar producer and a highly attractive market for Intertek’s solutions.

The caveats – what we do not know and risks to watch

Price and financial impact: The consideration, expected revenue contribution and margin impact are not disclosed. Without numbers, it is hard to gauge materiality.
Ramp-up and utilisation: Successful labs need steady throughput. The RNS does not disclose current capacity or utilisation rates.
Integration and execution: Moving from asset transfer to fully integrated Intertek systems, processes and branding takes work. Timelines are not disclosed.
Regulatory change: PV standards evolve. Keeping accreditations current and expanding scope requires ongoing investment.

What to watch next from Intertek

Operational timeline: Any update on when the lab is fully integrated under Intertek processes and booking revenue at steady state.
Accreditation scope: Confirmation of maintained or expanded ISO 17025, BIS and IECEE CB coverage under Intertek ownership.
Customer traction: First disclosed wins with Indian module makers or international entrants using the lab for harmonised testing.
Capacity investment: Any indication of capex to add new test lines or environmental chambers to meet India’s volume growth – not disclosed today.
Commentary in the next trading update: Management colour on solar-related order momentum and cross-sell into Intertek CEA’s inspection work.

Quick primer – the jargon in plain English

ATIC: Intertek’s umbrella for Assurance, Testing, Inspection and Certification services – the full quality stack.
Risk-based Quality Assurance: Focusing tests and checks where the greatest technical or commercial risks lie, saving time and cost.
ISO 17025: The international standard that confirms a laboratory is competent to carry out specific tests and calibrations.
BIS: Bureau of Indian Standards – India’s national standards body that grants certifications required for many products.
IECEE CB Scheme: A global system that lets countries recognise each other’s test results, cutting duplicate testing for international market access.

My verdict: a focused, strategically neat bolt-on

This looks like a smart, targeted acquisition that fits Intertek’s strengths. It adds accredited, on-the-ground capability in a market where solar volumes and compliance needs are both rising. The ability to combine local BIS approvals with IECEE CB credentials is commercially useful for domestic producers and foreign entrants alike.

Yes, we are missing the financials, so it is hard to call materiality. Even so, as a bolt-on that slots into ATIC and Intertek CEA’s end-to-end solar offering, the logic is tight. If Intertek can ramp utilisation, cross-sell inspections and maintain accreditation breadth, this should support growth in renewables assurance over the medium term.

Net-net: strategically positive, execution to watch. The next update with numbers will tell us how much it can move the needle, but the direction of travel – deeper in solar, closer to customers, faster market access – is the right one.